Abstract Increased levels of homocysteine (Hcy), known as hyperhomocysteinemia (HHcy), is an independent risk factor of various diseases. Clinical studies report that people born with severe HHcy develop skeletal malformations with weaker bone. Studies also report that altered mitochondrial dynamics and altered epigenetics contribute to weaker bones and bone diseases. Although Hcy-induced mitochondrial dysfunction has been shown to affect bone metabolism, the role of mitochondrial epigenetics (mitoepigenetics) has not been studied in bones. The epigenetics in mitochondria is interesting as the mitochondrial genome size is small (16 kb) with fewer CpG, and without histones and introns. Recently, fascinating works on epigenetics along with the discovery of histone-like proteins in mitochondria are giving exciting areas for novel studies on mitochondria epigenetics. There are mutual cause and effect relationships between bone, mitochondria, Hcy, and epigenetics, but unfortunately, studies are lacking that describe the involvement of all these together in bone disease progression. This review describes the reciprocal relationships and mechanisms of Hcy-bone-mitochondriaepigenetics along with a short discussion of techniques which could be employed to assess Hcy-induced anomaly in bone, mediated through alterations in mito-epigenetics.
Introduction
Many clinical and basic studies have shown the relationship between high homocysteine (Hcy) levels in serum and impaired bone health in children, adolescents, postmenopausal woman, and the elderly. Hcy is being proved as an independent risk factor of various diseases including bone diseases (osteoporosis, arthritis, fracture risk, and bone deformity) [1] [2] [3] . Studies also report that hyperhomocysteinemia (HHcy), an increased level of Hcy, affects mitochondria dysfunction and dynamics and that this process confirms the association between mitochondrial DNA, oxidative stress, and premature bone fragility [4, 5] . Mitochondria are the power house of the cells; they generate energy in the form of adenosine triphosphates (ATPs), and they are five times more prone to oxidative stress [6] . Mitochondria contain their own genome, also called as nucleoid, which is around 16 kb in size and does not contain histones and introns. Despite this, reports suggest that epigenetics play an important role in mitochondrial metabolism as well as other mechanisms. Interestingly, recent studies determined the role of DNA methylation, hydroxymethylation, and microRNA-based mechanisms which regulate mitochondrial functional integrity. The discovery of histone-like bodies in mitochondria also raises interest toward hidden molecules and mechanisms regulating mitochondria dynamics [7] . Bone has been studied with respect to mitochondrial aspects, but unfortunately, these studies are not directed toward epigenetic alterations induced with HHcy. These studies could certainly benefit from the discovery of novel mitochondrial epigenetic mechanisms and biomarkers for bone diseases. Hence, the current review describes the mutual associations of Hcy, mitochondria, epigenetics, and bone. This review also suggests the possible mitochondrial epigenetic (mitoepigenetic) mechanisms that impart bone weakness and disease progression, and affect bone metabolism. At last, potential techniques are discussed, which could be employed finding epigenetic mechanisms in impaired bone health.
Historical perspective and effect of homocystinuria on bone
The first study that reported the link between Hcy and pathological changes in bones, in patients with homocystinuria, was done by McKusick (1966) . Homocysteinuria is a genetic disorder caused by mutation in cystathioninebeta-synthase (CBS) gene [8] . Deficiency of the gene led to high level of Hcy in plasma. Homocystinuria manifests as a distinctive spondylo-epimetaphyseal dysplasia which is also characterized by skeletal deformities, osteopenia, elongated appendicular skeleton, and flattening of the vertebral bodies [9] [10] [11] . A recent study described that patients with good metabolic control of homocystinuria with a low-methionine diet prevented bone anomalies with an adequate BMD gain [12] . A meta-analysis study provided prospective evidence of Hcy association with significant increase of fracture risk. The study demonstrated increased Hcy increased risk of all fractures (RR 1.59, 95 % CI 1.30-1.96) and hip fracture (RR 1.67, 95 % CI 1.17-2.38). The same study also described that the risk was more pronounced in male subjects [3] . The study done with 3,502 subjects-years of follow-up determined 103 individuals with at least one osteoporotic fracture and the association of osteoporotic fractures with quartiles of Hcy (p = 0.047) [13] . A study with 1,475 postmenopausal women concluded significant risk to vertebral fracture with high plasma Hcy levels (OR 1.27, 95 % CI 1.04-1.58, p = 0.021) [2] . Herrmann et al. have explored the role of HHcy on bone remodeling primarily by decrease in osteoblast activity, increase in osteoclast activity, alteration in extracellular matrix, and decrease in blood flow [10, 14, 15] .
There have been various mechanisms described for the effect of Hcy on bone. Mice fed on high Hcy diet showed high serum Hcy concentration (102.2 ± 64.5 micromole/l) as compared to normal standard diet-fed mice (2.8 ± 1.5 micromole/l) and appear to have impaired fracture healing [16] . The study from our laboratory on genetic hyperhomocysteinemic mice (CBS±) showed decrease in boneblood flow and increase in NOX-4, iNOS (inducible nitric oxide synthase), MMP-9 (matrix metalloproteinase) protein, MMP9 activity along with decrease in Trx-1 (thioredoxin), eNOS (endothelial nitric oxide synthase), and NO (nitric oxide) bioavailability [17] . HHcy has been described as altering the redox regulatory mechanism in the osteoblast by activating PP2A and deranging FOXO1 and MAPK signaling cascades that eventually shifted the OPG\RANKL (receptor activator of nuclear factor kappa-B ligand) ratio toward increased osteoclast activity and decreased bone quality [18] . Hcy lowering treatment, folate, and vitamin B12 have shown benefits, with reduced risk of hip fracture [19] . Increased homocysteine also activated JNK signal via ROS and induced the apoptosis of bone marrow mesenchymal stem cells (BMSCs) [20] . Collagen cross-linkers are determinants of bone quality, and Hcy is known to affect collagen cross-link by decreasing enzymatic cross-link and increasing non-enzymatic cross-link [21] . A study with 10 homocystinuric patients determined significantly lower collagen I C terminal telopeptides (ICTP) which is a cross-linked telopeptide from the C-terminal non-helical part of collagen I [22] . Treatment of Hcy on MC3T3-E1 (pre-osteoblast cells) for 21 days led to significant decreases in collagen cross-linking along with the activation of PTK2-PXN-CTNNB1 pathway [23] . Hcy treatment to osteoblastic cells led to an increase in release of mitochondrial cytochrome c. Treatment also triggered ER stress by increased expression of glucose-regulated protein 78, inositol-requiring transmembrane kinase and endonuclease 1a (IRE-1a), spliced X-box binding protein, activating transcription factor 4, and C/EBP homologous protein [24] . There is a significant correlation found between serum and bone homocysteine level, and an increased level of homocysteine in bone was also found to affect bone morphology [1] .
Bone mineral density (BMD), a diagnostic parameter of osteoporosis, is significantly decreased with increased levels of Hcy. Hence, homocysteinuria increases the risk of osteoporosis by decreasing BMD. Numerous reports also suggest that increased plasma Hcy reduces BMD and increases fracture risk [25] [26] [27] [28] . On the contrary, a few epidemiological studies have determined that no significant relationship exists between plasma Hcy and fracture risk [26, 29] . Because of contradictory results with the studies, more studies are required to come to a final conclusion. The Hcy-induced fracture risk could be assessed by analyzing bone metabolism markers which are divided into bone formation (alkaline phosphatase, pro-collagen type I N and C-terminal peptides, osteocalcin) [15, 25, [29] [30] [31] and bone resorption (collagen I, beta-crosslaps, urinary deoxypyridinoline cross-links, tartrate-resistant acid phosphatase 5b) [30, 32, 33] . However, metabolism anomalies arise after disturbance of normal axis between bone formation and resorption. Existing clinical and animal studies report the action of Hcy is through shifting the bone metabolism to bone resorption. Kim et al. have shown the effect of Hcy on primary human osteoclasts collected from 10 healthy male donors. They determined significant stimulation of resorption activity. Significant increase in tartrate-resistant acid phosphatase (TRAP; maximum increase of 24 %) and cathepsin K (CK; maximum increase of 24 %) activity confirmed increase rate of bone resorption with exogenous Hcy administration with decreasing concentrations of folate, and B6 and B12 markers [14] .
Bone and mitochondrial metabolism
The number and activity of mitochondria differ in different cells dependent upon energy demand of the cell type. Bone cells contain a large number of mitochondria, and mitochondrial dysfunction may contribute to bone impairment. It was reported that the content of mitochondria was found to be decreasing in periosteum osteoblasts during the life span of the rat from weeks 1 to 104 [34] . In another study, authors have measured the levels of mRNA derived from mitochondrial genes in healing fractures of young, adult, and old rats and found that older rats exhibit reduced mitochondrial gene expression during fracture repair [35] . In humans, few studies have addressed association between mitochondrial DNA, oxidative stress, and premature bone fragility [4, 5] . At the tissue level, bone metabolism is linked to coordinated function of osteocytes, osteoblasts, and osteoclasts. Osteoblasts have been referred to as 'bone builders,' and their increased activity was found to increase the number of mitochondria during bone formation. Cultured osteoblasts can produce energy via glycolysis, citric acid cycle, and beta-oxidation pathways [36, 37] . Besides energy regulation, mitochondria also regulate life of bone cells, and thus, mitochondria health is important as well for proper bone functioning.
Osteoblast metabolism is based on the generation of products of bone-matrix production and alkaline phosphatase activity. It has been reported that glucose utilization is proportional to alkaline phosphatase activity as measured by using [(18)F]-fluorodeoxyglucose in human osteoblastlike cells in vitro [38] . The primary osteoblast cells derived from fetal rat calvaria were kept on differentiation with ascorbate treatment, and bioenergetics was measured. The rate of respiration, ATP production, and ATP content were found to be increased after 14 days of osteoblast differentiation as compared to immature cells. Likewise as compared to immature cells, mature cells were reported to have high-transmembrane-potential mitochondria as measured by using JC-1 (5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethylbenzimidazolylcarbocyanineiodide) dye uptake [39] . Proper mitochondrial function is linked to the maintenance of the phosphocreatinine pool which is generated from creatinine by mitochondrial creatine kinase. Phosphocreatinine then diffuses from mitochondria via voltagedependent anion channel to the cytosol where creatinine kinase can generate ATP for utilization. Creatinine kinase is therefore a pivotal enzyme for cellular energy metabolism of osteoblasts, and it has been seen that supplementation of creatinine to cultured osteoblast not only increases metabolic activity but also enhances their survival [40] [41] [42] . Mitochondria also produce citrate which is important to maintain bone nanostructure since citrate covers approximately one-sixth of the hydroxyapatite surface [43] . Another important enzyme that is produced by mitochondria of osteoblasts is cytochrome c oxidase which determines apoptotic events in osteoblast cells [44] [45] [46] .
Mitochondrial quality is an important determinant of osteogenic differentiation capacity and viability of human mesenchymal stem cells (hMSCs) [47] . Different reports suggest the metabolic status of cells during differentiation including few studies on mitochondrial bioenergetics and regulation at the time of bone cells differentiation. Chen et al. [48] reported that undifferentiated hMSCs showed high level of glycolytic enzymes and lactate production, while differentiating hMSCs exhibited more mitochondrial DNA copy number, protein subunits of respiratory enzyme, rate of oxygen consumption, and intracellular ATP content. The increase in mitochondrial bioenergetics indicated upregulation of aerobic mitochondrial metabolism. An et al. [49] showed increase in mitochondrial biogenesis during Wnt-induced osteoblastic differentiation of murine mesenchymal C3H10T1/2 cells. However, the biogenesis was significantly attenuated with zidovudine which is an inhibitor of mitochondrial biogenesis. Peroxisome proliferator-activated receptor gamma coactivator1alpha (PGC-1a) is a known regulator of mitochondrial biogenesis and together with NR4A/NGF-1b orphan nuclear receptor (NR) regulated primary mouse osteoblasts gene expression upon treatment with parathyroid hormone [50] . Osteoblast also differentiated into osteocytes which are relatively inert cells but capable of molecular synthesis and modification, as well as transmission of signals over long distances [51] . Osteoclasts also have high energy demands, and therefore, they are rich in mitochondria [52] . The differentiation of osteoblasts to osteocytes led to increased expression of glycolytic enzymes and mitochondrial heat shock protein 70 (HSP 70). Osteoclasts are prone to mitochondrial dysfunction due to their high susceptibility for ROS.
Homocysteine, bone, and mitochondria One study reported that HHcy contributes to the development of osteoporosis by reducing bone formation. This study demonstrated that Hcy-induced apoptosis in primary human bone marrow stromal cells (hBMSC) and the human bone marrow stromal cell line (HS-5) was mitochondrialdependent since caspase-3 and caspase-9 were involved. The same study confirmed that Hcy increased cytochrome c and ROS and activated the NF-jB pathway [53] . We earlier proposed that Hcy increases ROS that directs mitochondrial membrane permeability transition (MPT) that further allows the extrusion of proteins through mitochondria in osteocytes [54] . We also proposed the pathway of MMPs activation in bone remodeling during HHcy [54] . MMPs play a very important role in bone turnover processes. Different MMPs, for example MMP-1, MMP-2, MMP-3, MMP-9, MMP-10, MMP12, MMP-13, MMP14, are expressed in different bone processing and execute specific functions [55] . Hcy is well known to activate MMPs and thus probably involves proteases in mediating bone pathogenesis [54, 56] . Moreover, absence of enough studies in Hcy-mediated bone remodeling through mitochondria warranted important studies to fill out the knowledge gap in the proposed area.
Epigenetics underlying bone metabolism
Epigenetics is the study of heritable changes in gene activity. The study does not involve changes in the DNA nucleotide sequence but affects on gene expression. Tight control of genetic mechanisms occurs under the influence of several important epigenetic mechanisms, for example, DNA methylation, non-coding RNA (microRNA), histone modification, ubiquitylation, ADP ribosylation, biotinylation, and sumoylation. These processes not only control the genetic regulation but also control development, cell differentiation, and aging. Besides, these modifications can also be treated as marker for the disease event and termed as epigenetic biomarker.
Role of DNA methylation
There have been several studies reported for these modifications in bone and bone cells. Investigators have determined that in case of osteoarthritis (OA), the level of MMP-13 is increased in OA chondrocytes which was associated with demethylation of CpG sites in the MMP-13 promoter [57] . In another study in human chondrocytes, authors have find out demethylation of MMP13 at -110 and -299 bp which was associated with increased levels of MMP-13 gene expression [58] . Another gene that is found to be associated with catabolic activity in cartilage is the inducible nitric oxide synthase (iNOS). The association between demethylation of specific NF-kappaB-responsive enhancer elements and the activation of iNOS transactivation in human OA chondrocytes was seen, which was consistent with the differences in methylation status observed in vivo in normal and human OA cartilage and, importantly, shows association with the OA process [59] . The pattern of methylation (hypo-or hypermethylation) has earlier been seen in rheumatoid arthritis synovial fibroblast (RASF) by Nakano et al. [60] . Besides that, an altered methylation status in rheumatoid arthritis has been found for many genes, such as DR3 [61] , IL6 [62, 63] , IL10 [64, 65] , IL1R2 [65] , and CXCL12 [66] . The functional consequence of altered DNA methylation is also evident by one of the earlier studies that explained the increased risk to develop RA (rheumatoid arthritis) in women. Authors of this study observed the pattern of X chromosome inactivation and found that female RA patients exhibited increased skewed X chromosome inactivation pattern as compared to controls [67] . Few recent studies in systemic lupus erythematosus (SLE) enlighten the significance of hypomethylated genes that were concerned with various pathways of SLE pathogenesis, such as defense response, cell activation and proliferation, immune response, and cytokine production [65] . Besides that, genome-wide DNA methylation arrays identified global DNA methylation changes in SLE T cells as compared to healthy T cells [68] . In addition, differentially methylated genes were found to be having potential to be used as epigenetic biomarkers for SLE pathogenesis [69] .
Role of histone modifications
Histone modification is a dynamic process that leads to chromatin remodeling and modulates gene expression. Histones (H2A, H2B, H3, and H4) form an octamer complex and connected through H1 and around this DNA wraps and packaged. The histones could be modified by several posttranslational modifications, such as acetylation, methylation, phosphorylation, ADP ribosylation, sumoylation, and biotinylation. The central mechanism of histone modification is controlled by histone acetylation/deacetylation which further controls gene expression. Histone acetyltransferases (HAT) loosens the histone-DNA interactions, relaxes the chromatin, and favors transcription of genes, while histone deacetylases (HDAC) increases histone-DNA interaction and chromatin condensation, and attenuates transcription machinery [70] . HDAC inhibitors were profoundly used to alleviate osteoblast and osteoclast differentiation, such as sodium butyrate, valproic acid, MS-275, and TSA [71, 72] . These agents were found to influence differentiation by influencing genes associated with osteoblast/osteoclast differentiation (e.g., type I collagen, bone sialoprotein, osteopontin, osteocalcin, ALPL, OSX and RUNX2 cathepsin K, calcitonin receptor, and OSCAR).
Role of microRNA
MicroRNAs (miRNA) are 20-22 nucleotides long, processed from stem loop pre-miRNAs to mature miRNAs, and regulate a large number of target genes by binding to the 3 0 region of their corresponding messenger RNA (mRNA). There are many reports available for many miRs regulating osteoblast differentiation [73] . Some of them are miR-30, mir433, and miR-335 by directly targeting osteogenic transcription factor RUNX2 [74] [75] [76] . Likewise, miRs also regulate osteoclast differentiation, for example, miR-21 by targeting programmed cell death 4 (PDCD4) protein levels [77] and miR-155 by targeting microphthalmia-associated transcription factor (MITF) [78] .
Epigenetics and mitochondria
The mitochondria genome size is 16,569 bp, represents \1 % of total cellular DNA, and encodes 13 proteins in the electron transport chain (ETC) and the displacement loop (D-loop), two rRNA (rRNAs), and 22 tRNAs necessary for the translation of mitochondrial genes. Mitochondrial gene products are essential for normal cellular function. More than 200 different molecular defects have been reported in patients with mitochondrial diseases. The number of mitochondria varies from tissue to tissue. It contains fewer CpG dinucleotides (435) than genomic DNA and lacks the conventional CpG islands that are found in genomic DNA. Furthermore, mitochondrial genome does not contain retrotransposons (LINE-1 and Alus), which are abundantly (*40 %) present in human genome. The lack of histones in mitochondrial genome also suggests an important role for DNA methylation in mitochondrial DNA (mtDNA) stability and function. It is earlier reported that mtDNA was less methylated, as compared to nuclear DNA, in loach embryos, and the same study reported the presence of DNMT activity in mitochondria [79] . After that, mtDNA methylation was reported in human [80] and mammals [81] . The mitochondrial DNMT was found different than nuclear one [82] . MtDNA methylation is done by means of 5-methylcytosine and 5-hydroxymethylation and has been reported in many disease-related studies [83] .
Apart from this, many studies report role of mtDNA methylation in different disease progression. The absence of histones in mitochondria did not open the epigenetic area of histone modifications; however, a report suggests the presence of histone family members in mitochondria [7] . More studies are warranted to come with existing contradictory reports and explore histone-based modifications in mitochondria. Likewise, there is no report, to date, that identifies mitochondria-allied disorders by directly affecting microRNAs. Nevertheless, microRNAs have been seen to be involved in mitochondrial metabolism regulations; for example, miR-210 is shown to regulate electron transport chain and tricarboxylic acid cycles [84] , and miR-30 is observed for its role in mitochondrial fission targeted through p53 and dynamin-related protein-1 (DRP-1) [12] . In rats, a small pool of microRNA, identified in highly purified liver-derived mitochondria, appears to regulate the expression of genes related to apoptosis, cell proliferation, and cellular differentiation [85] . Figure 1 describes the several mechanisms associated with mitochondria epigenetic regulations.
Hcy-bone-mitochondria-epigenetics
The previous studies showed the relations in between Hcy, epigenetics, bone, and mitochondria (connection shown in Fig. 2 ), but the reports are lacking which unite these together with direct research in bone anomaly induced by homocysteinuria and mediates through alterations of mitochondrial epigenetics. We and others have already established that Hcy influences epigenetic mechanisms along with mitochondrial dysfunctions, and therefore, research is required to find out their role in bone weakness during homocysteinuria. The research will provide a novel milestone in the bone science.
Supporting techniques
Performing epigenetics studies in bone mitochondrial genome is not easy as in the nuclear genome. One should have to be very careful from isolating purified mitochondria to perform epigenetic studies in bone mitochondria. Another difficulty is the mitochondria genome size that is reported to consist of fewer CpG and is devoid of histones and introns. There are several techniques that can be used to perform Hcy-induced epigenetic modifications in bone mitochondria.
Bisulfite sequencing
This technique is used to check bisulfite modification of DNA and used to differentiate between cytosine bases in methylated CpG and unethylated CpG sites. Methylated cytosine bases have a methyl group bound to the carbon-5 position of their pyrimidine ring. With bisulfite treatment, 5-mC (5-methylcytosine) residues are protected, but cytosine residues are converted to uracil. A number of downstream applications can be employed to estimate the level of methylation in the given sample such as sequencing of methylated DNA and polymerase chain reaction specific to methylated region. The technique is advantageous in order to assess even a single CpG site and is relatively quick to perform. Another advantage of bisulfite modification is that it does not differentiate between 5-mC and 5-hydroxymethyl cytosine (5-hmC). The drawback of bisulfite sequencing is that the technique does not estimate the percentage of methylation at a given site.
Methylation-based arrays
For high-throughput analysis of methylated DNA, the arrays specific for methylated DNA are available. Although Fig. 1 Possible epigenetic mechanisms in bone mitochondria. Here, ncRNA non-coding RNA, miRNA microRNA, piRNA piwi RNA, lnc long non-coding RNA, SAM S-adenosylmethionine, SAH S-adenosylhomocysteine, hmC hydroxymethycytosine Fig. 2 Figure showing mutual relations between homocysteine, bone, mitochondria, and epigenetics these arrays are specific to bind nuclear targets, those targets may be specific to bone mitochondrial gene functions.
Biochemical epigenetic assays
Epigentek (Epigentek, Farmingdale, NY, USA) has launched several kits for determining DNA, RNA methylation, DNA methyltransferase assay, DNA demethyase assay, methylated DNA immunoprecipitation, methylated DNA quantification (5-hydroxymethylation assay, 5-methylacytosine estimation), and methyl-DNA binding protein Chip estimation. There are several other kits available to quantify histone modification too. Depending upon the need, these kits could be explored for their use in bone mitochondrial epigenetics projects.
MicroRNA profiling
The profiling of microRNA in test sample can be performed through array-based methods and compared to control sample. This will give some microRNAs which could be associated with mitochondrial epigenetics. Finding individual microRNA and their downstream targets could further throw light for individual important microRNA for the research projects. After that, quantitative PCR methods would benefit for assessing individual microRNA role in bone disease progression. The use of mimics (microRNA) and anti-microRNA (antagomiR or miR inhibitors) designed for individual microRNA would further confirm the regulation of microRNA for mitochondria-related bone diseases.
Chromatin modifications
Although mitochondrial DNA lacks histones, they are packed with proteins to form nucleoids. A Chip assay can be designed to analyze protein-DNA interactions followed by downstream analysis of the purified DNA/protein and could be useful for mitochondrial epigenetics in bone.
Transcriptome sequencing
The purified bone mitochondrial RNA can be explored by next-generation sequencing to identify relative transcript abundance, RNA variation, and posttranslational modifications. A relatively small genome could further be analyzed for global schema of polycistron cleavage using parallel analysis of RNA ends (PARE).
Summary and future directions
In summary, we have discussed the relationship of Hcy, bone, mitochondria, and epigenetics. Although it is reported that homocystenuria leads to dysfunction of bone, the epigenetic pathways in bone mitochondria that lead to bone pathology have not been discussed. This suggests that studies should focus on the direction of Hcy-induced mitochondrial epigenetics in bone, and these studies could explore novel mechanisms during disease pathology. For example, we are proposing a mechanism of mito-epigenetic remodeling that leads to bone function impairments during HHcy as shown in Fig. 3 . HHcy causes mito-redox stress that alters mitochondrial dynamics and mito-epigenetics (DNA methylation, DNA hydroxymethylation) concomitant with Nhomocysteinylation of collagen 1. These altered events affect MMPs/TIMPs axis along with collagen/elastin ratio and eventually impair bone structurally and functionally.
In conclusion, we highlighted interactions between Hcy, bone, mitochondria, and epigenetics and presented possible mechanisms for disease progression. We also discussed in short epigenetics-related techniques which can be employed to find out epigenetic alterations in mitochondria during Fig. 3 Schematic representation of proposed mechanism of mitoepigenetic remodeling and change in bone structure/function during genetic hyperhomocysteinemia. The central hypothesis of this proposal is that HHcy contributes to mito-epigenetic remodeling (DNA methylation, DNA hydroxymethylation) mediated bone-matrix feebler through N-Hcy-collagen 1, in part, by altering mitochondrial remodeling. These events disturb normal MMPs/TIMPs axis and collagen/elastin ratio, and eventually led to bone function impairments which could be determined by bone mineral density, assessing osteoclast/osteoblast differentiation and bone-blood flow. Here, MMP matrix metalloproteinases, TIMP tissue inhibitor of matrix metalloproteinases, mito-fusion mitochondrial fusion, mito-fission mitochondrial fission Hcy-induced bone anomaly. Identifying these important pathways and epigenetic molecules would certainly benefit epigenetic molecular targets that could be used to attenuate disease pathology or to be used as biomarker for bone diseases. In our opinion, epigenetic approaches with bone mitochondria during HHcy are very promising, and further studies are required to determine pathways/molecules that would improve bone disease and alleviate therapeutic directions.
